Scientific References
| Systemic Enzyme Poster References |
 |
|
|
Please use our Search feature to find pacific information about systemic enzyme support and conditions treated. |
||
Accessed: 06/19/08.
[2] - EC Numbers. “Recommendations of the Nomenclature Committee of
the International Union of Biochemistry and Molecular Biology on the
Nomenclature and Classification of Enzymes by the Reactions they Catalyse”. Located at:
http://www.chem.qmul.ac.uk/iubmb/enzyme/
Accessed: 06/19/08.
[3] - Gonias SL, Pizzo SV.
Conformation and protease binding
activity of binary and tertiary human alpha 2-macroglobulin-protease
complexes. J Biol Chem. 1983 Dec 10;258(23):14682-5.
[4] - Mettenburg JM, Gonias SL.
Beta-amyloid peptide binds
equivalently to binary and ternary alpha2-macroglobulin-protease
complexes. Protein J. 2005 Feb;24(2):89-93.
[5] - LaMarre J, Wollenberg GK, Gonias SL, Hayes MA.
Cytokine binding and clearance properties of proteinase-activated
alpha 2-macroglobulins. Lab Invest. 1991 Jul;65(1):3-14.
[6] - French K, Yerbury JJ, Wilson MR. Protease activation of alpha2-macroglobulin modulates a
chaperone-like action with broad specificity. Biochemistry. 2008 Jan 29;47(4):1176-85.
[7] - Lauer D, Reichenbach A, Birkenmeier G.
Alpha
2-macroglobulin-mediated degradation of amyloid beta 1--42: a
mechanism to enhance amyloid beta catabolism. Exp Neurol. 2001
Feb;167(2):385-92.
[8] - Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ.
Degradation of amyloid beta-protein by a serine
protease-alpha2-macroglobulin complex. J Biol Chem. 1996 Apr
5;271(14):8443-51.
[9] - Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA,
Paul SM.
alpha2-Macroglobulin as a beta-amyloid peptide-binding
plasma protein. J Neurochem. 1997 Jul;69(1):299-305.
[10] - Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel
NG, Sahasrabudhe S.
Alpha2-macroglobulin associates with beta-amyloid
peptide and prevents fibril formation. Proc Natl Acad Sci U S A.
1998 Mar 17;95(6):3275-80.
[11] - Mettenburg JM, Gonias SL.
Beta-amyloid peptide binds
equivalently to binary and ternary alpha2-macroglobulin-protease
complexes. Protein J. 2005 Feb;24(2):89-93.
[13] - Misra
[14] - Feldman SR, Ney KA, Gonias SL, Pizzo SV.
In vitro binding and
in vivo clearance of human alpha 2-macroglobulin after reaction with
endoproteases from four different classes. Biochem Biophys Res Commun. 1983 Jul 29;114(2):757-62.
[15] - Vassilenko A.M., Fessenko V.I., Schvets S.V. Efficacy of systemic enzyme therapy in the treatment
of patients with chronic hepatitis B. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 93-97.
[16] - Orekhov A.N., Kalenich O.S., Tertov V.V., Novikov I.D.
Lipoprotein Immune Complexes As Markers of Atherosclerosis Lipoprotein Immune Complexes As Markers of
Atherosclerosis. Inter. Journal of
Tissue Reactions 1991, Vol. XIII, No. 5, pp. 233-236.
[17] - Dzivite I., Sochnevs A., Stauder G., Zeibarts M.,
[18] - Sledzevskaya I.K., Loboda M.V., Kolesnik E.A., Babiy L.N.,
Fisenko L.I.
Systemic enzyme treatment as a method of secondary
prevention in patients after myocardial infarction in the
rehabilitation period. II Mediterranean Congress of Physical
Medicine and Rehabilitation, 20-23 May, 1998, Valencia, Spain.
Abstracts- pp. 137 489 KA (19-08-3).
[19] - Wrba H.
Systemic Enzyme Therapy - Newest Status and Progress.
Therapie Woche 1987, Jahrgang 37, No. 7
SO 11 (19-02-3).
[20] - Samtsov A.V., Mazurov V. I., Tabachnov V.V.
Systemic enzyme
therapy in the treatment of neurodermitis (atopic dermatitis)
patients. Skin and Venereal Diseases Department of
Sankt-Petersburg’s Military Medicine Academy Conference "New aspects
of systemic enzyme therapy", Moscow, 1999.
[21] - Sledzevskaja U. K., Šumakov V. A., Bratus V. B., Babij A.,
Malinovskaja U. Z., Gavrilenko T. U., Terzov A. U.
Systemic enzyme
therapy in the treatment of patients with myocardial infarction. Žurnal praktièeskogo vraèa 1997, No. 3, pp. 43 – 44.
[22] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova
T.G.
The Efficacy of Systemic Enzyme Therapy in the Treatment of
Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol.
XIII, No. 3/4, pp. 85-91.
[23] - Kartvelishvili E., Shalamberidze L., Torondjadze M.
The
results of long-term use of Wobenzym in complex management of Behcet's disease. International congress "Advances in Immunology and Allergology at the Treshold of the XXI Century" May 3-6, 2000,
[24] -
[25] - Rammer E, Friedrich F.
Enzyme therapy in treatment of mastopathy. A randomized double-blind clinical Study.
Wien
Klin Wochenschr. 1996;108(6):180-3.
[26] - F. W. Dittmarl, W. Luh.
Treatment of fibrocystic
mastopathy with hydrolytic enzymes. International J. of Experimental
and Clinical Chemotherapie 1993: Vol. 6, No. 1, pp. 9-20 WE 13
(5-03-1) = WE 49 (5-04-1) nìm.
[27] - Sledzevskaya I.K., Loboda M.V., Kolesnik E.A., Babiy L.N.,
Fisenko L.I.
Systemic enzyme treatment as a method of secondary prevention in
patients after myocardial infarction in the rehabilitation period. II Mediterranean Congress of Physical
Medicine and Rehabilitation, 20-23 May, 1998, Valencia, Spain.
Abstracts- pp. 137 489 KA (19-08-3).
[28] - Sledzevskaja U. K., Šumakov V. A., Bratus V. B., Babij A.,
Malinovskaja U. Z., Gavrilenko T. U., Terzov A. U.
Systemic enzyme
therapy in the treatment of patients with myocardial infarction. Žurnal praktièeskogo vraèa 1997, No. 3, pp. 43 – 44.
[29] - Kovalenko V.N., Sledzevskaya I.K., Ryabokon E.N., Gavrilenko
T.I., Terzov A.I. N.D.
Strazhesko New approaches to modern
cardiology based on systemic enzyme therapy. Int. J. Immunotherapy
2001, Vol. XVII, No. 2/3/4, pp. 101-111.
[30] - Mazurov V.I., Stolov S.V., Linetskaya N.E., Onyschenko E.F.
Systemic enzyme therapy in the complex treatment of angina pectoris.
Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 113-120.
[31] - Schved N.I., Martyniuk L.P.
Clinico-laboratory evaluation of
treatment efficacy in chronic pyelonephritis patients with Wobenzym.
Vratschebnaya praktika 1997, 4, 38-42.
[32] - Schlüter. P.
Phlogenzym® in patients with relapsing urinary
tract infections: Efficacy & Tolerance. Schlüter. Gartenstraße 96,
D-69502 Hemsbach, Germany. Report by: MUCOS Pharma GmbH & Co, Abt.
Klinische Forschung, Kirchplatz 8, D-82538 Geretsried, Germany
[33] - Borisov O.V.
Coenzyme metabolic assurance of patients with
recurrent nephrolithiasis in the complex treatment by systemic
enzyme therapy. Urologia 1998, 3, pp. 29-35.
[34] - Borisov A.V., Ukhal M.I., Kabak Yu.A., Borisov S.A.
Immunological aspects of systemic enzyme therapy (SET) in the
complex treatment of recurrent nephrolithiasis. 1st National
Congress of the Ukraine on Immunology, Allergology, and
Immunorehabilitation.
[35] - Stauder G., Wood G., Paczek L.
Enzyme Therapy in Diabetic
Nephropathy – Experimental and First Clinical Data. 6th Taormina
Course of Nephrology. October 20th - 22th, 2000, pp. 227-232,
Editoriale Bios 2000
PZ 22 (5-14-3)-(19-11-3).
[36] - Friedrich, F. Wobenzym®
in the Treatment of Chronic Pelvic Inflammatory Disease. Study NR.:
MU-89210. Germany Report provides through: PHARMASCRIPT, Kathi Kobus
increase 1, W-8190 Wolf-advice-live, to Germany Report: 30. 5. 1989.
[37] - Dittmar F.-W., Weissenbacher E. R.
Therapy of adnexitis -
enhancement of the basic antibiotic therapy with hydrolytic enzymes.
International Journal of Experimental and Clinical Chemotherapy
1992: Vol. 5, No. 2, pp. 73-81.
[38] - Nouza K.
Physical activity and immune system. Systemic enzyme
therapy in prevention and treatment. Medicina Sportiva Boh. Slov.
1997, Vol. 6., No. 2, pp. 41 - 45.
[39] - Wald M.
Diagnosis and treatment of lymphedema. Interní
medicína pro praxi 2003, č. 8, str. 415-417.
[40] - Kafková H., Kojanová M.
Lymphedema.
Postgraduální medicína
2003, 5 (6), pp. 626 – 633.
[41] - Dzupina A., Morvay P., Dzupinova M.
Systemic enzyme therapy
and complex decongestive therapy in the patients with primary and
secondary lymphedema of lower extremity.
Lymfo 2000, Praha 13. - 14.
10. 2000. Praktická flebologie - supplement 2000, Roè. IX, str.
23-27. (17-13-2)-(17-12-1).
[42] - Dusková M, Wald M.
Orally administered proteases in aesthetic
surgery. Aesthetic Plast Surg. 1999 Jan-Feb;23(1):41-4.
[43] - Dzupina A., Morvay P., Dzupina M.
Proteolytic enzymes in
lymphedema therapy. 41st Annual World Congress - ICA'99,
International College of Angiology, Sapporo, Japan, July 3-10, 1999,
Scientific Posters pp. 76.
[44] - Korpan MI, Fialka V.
Wobenzyme and diuretic therapy in
lymphedema after breast operation. Wien Med Wochenschr.
1996;146(4):67-72; discussion 74.
[45] - Kasseroller R., Wenning H.G.
Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema
after axillary dissection due to mammary cancer. The European
Journal of Lymphology, 2002-2003, Vol. 10, No. 37-38, pp. 18-26,
[46] - Kopadze, T.Sh., Natsvlishvili, G.A., Tvaladze, M.G.,
Avazashvili, D.N.
Application of Wobenzym and Phlogenzym to the
angiology and vascular surgery. Georgian Medical News 2001, No. 2,
(serial No.71), pp. 27 – 29.
[47] - Koshkin V.M., Kirienko A.I., Leontjev S.G., Agafonov V.F.
Systemic enzyme therapy of lower limb postphlebitic syndrome.
Angiology and vascular surgery 2000, Vol. 6, No. 2, pp. 61 – 64.
[48] - Džupina A., Džupinová M.
Wobenzym in the treatment of Thrombophlebitis. Praktická flebologie 1998, Roè. 7, è. 1, str.
28-30 (17-12-3).
[49] -
Vallery M. Koshkin,, D.M.Sci.
Wobenzym® in the Treatment
of Acute Thrombophlebitis. PharmaScript, Kathi-Kobus-Steig 1,
D-82515 Wolfratshausen, Germany.
[50] - Kvantchakhadze R.G.
Wobenzym in the complex treatment of
autoimmune thyroiditis. International Journal on Immunorehabilitation, 2002,
Vol. 4, No. 1, pp. 114.
[51] - Vokálová I.
Systemic enzyme therapy in the treatment of
children with recurrent infections of respiratory tract. VOX
PEDIATRIAE 2003, Vol. 2., No. 9, pp. 29 – 30.
[52] - Shved M.I., Dubkova G.I.
Therapeutic efficacy of Wobenzym in
patients with focal pneumonia. Visnik naukovych doslidženij 1999,
No. 2, pp. 79-82.
[53] - Mertin J.1, Stauder G., ESEMS working group.
Use of oral
enzymes in multiple sclerosis patients. Inter. Journal of
Tissue Reactions 1997, Vol. XIX , No.1/2, pp 95.
[54] - Krejcová, H.
Wobenzym® and Wobe-Mugos® in the Treatment of
Multiple Sclerosis.
PharmaScript, Kathi-Kobus-Steig 1, D-82515 Wolfratshausen, Germany.
[55] - Stauder G., Donnerstag B.,
[56] - Milus I.E.
Wobenzym in the treatment of patients with
psoriasis. Zurnal dermatologii i venerologii 1998, 2 (6), 35-36.
[57] - Schlüter, P.
Phlogenzym® in the Treatment of Chronic
Prostatitis. PharmaScript, Primelweg 2, D-82538 Geretsried, Germany
Date of report: October 30th, 1997.
[58] - Schlüter P.
Efficacy and tolerance of oral enzyme therapy in
chronic prostatitis: Results of a double-blind therapy study. European Journal for Infectious and Immunological Diseases 1998,
Vol. 2, pp. 57-69.
[59] - Izbasarov A.I., Ismoldaev E.S., Khusainov T.E.
Special
treatment of patients suffering from a mixed copulatory dysfunction
with interoreceptive syndrome. 3rd Urology Congress of Khazakhstan
May 25-26, 2000., Almaty.
[60] - Nouza K., Madar J.
Immunomodulation in the treatment of
reproduction disturbances. American Journal of Reproductive
Immunology 2001, Vol. 46, No. 1, pp. 106.
[61] - Ivaniyta L.I., Ivaniyta S.O., Kornatskaya A.G., Belis N.I.,
Kondratiyk.
Systemic enzyme therapy in the treatment of chronic salpingitis and infertility. Farm. Zh. (
[62] - Dittmar, F.-W.
Enzyme therapy - a method of immune therapy
for immunologically caused habitual abortion. Forum Immunologie
2000, No. 3/2000, II - VIII.
[63] - Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M.
Oral enzyme
combination versus diclofenac in the treatment of osteoarthritis of
the knee--a double-blind prospective randomized study. Clin
Rheumatol. 2004 Oct;23(5):410-5. Epub 2004 Jul 24.
[64] - Klein G, Kullich W, Schnitker J, Schwann H.
Efficacy and
tolerance of an oral enzyme combination in painful osteoarthritis of
the hip. A double-blind, randomised study comparing oral enzymes
with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2006
Jan-Feb;24(1):25-30.
[65] - Tilwe GH, Beria S, Turakhia NH, Daftary GV, Schiess W.
Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthrosis of knee joint: an open
randomized controlled clinical trial. J Assoc Physicians India. 2001
Jun;49:617-21.
[66] - Guseinov N.I.
Wobenzym in therapy of rheumatoid arthritis.
International Journal on Immunorehabilitation 2001, Vol. 3, No. 2,
pp. 73-74.
[67] - Shalamberidze L., Kartvelishvili E., Astvatsaturova T.
The
results of long-term use of Wobenzym in complex management of
rheumatoid arthritis. International congress "Advances in Immunology
and Allergology at the Treshold of the XXI Century" May 3-6, 2000,
[68] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova
T.G.
The Efficacy of Systemic Enzyme Therapy in the Treatment of
Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol.
XIII, No. 3/4, pp. 85-91.
[69] - Klein G., Kullich W.
Pain Reduction in Rheumatic Diseases by
Oral Therapy with Enzymes. Wien. Med. Wschr. 1999, 149, pp. 577-580.
[70] - Szilasiová A., Macejová Ž., Jautová J., Pundová L.
Our
experience with Wobenzym in the treatment of patients with
rheumatoid and psoriatic arthritis. Prakt. Lékař 1998, Vol. 78,
No. 7, pp. 366-368.
[71] - Siziakina L.P., Artemenko N.A.
Clinical and immunological
criteria of activity of different rheumatic arthritis courses and
their treatment by Wobenzym. III. Internat. Congress on
Immunorehabilitation and Rehabilitation in Medicine, Eilat, Israel,
1997.
[72] - Kovalenko V.M., Golovkov Y.Z.
New possibilities of basic
therapy in patients with rheumatoid arthritis on the basis of
systemic enzyme therapy. Reumatologia 1998, Suppl Vol. XXXVI,
[73] - Shaivok A.V., Movsisyan G.R., Stolyarova A.V.
Wogenzym(R) in teh Treatment of Patients with Juvenile Chronic
Arthritis. INt. J.
Immunotherapy XIII(3/4) 93-96 (1997).
[74] - Kovalenko V.,Golovkov Y., Golovatcky I.
Using of systemic enzymotherapy for treatment of rheumatoid arthritis.
Rheumatologia
1998, Suppl., Vol. XXXVI,
[75] - Szilasiová A., Macejová Ž., Jautová J., Pundová L.
Our
experience with Wobenzym in the treatment of patients with
rheumatoid and psoriatic arthritis. Prakt. Lékař 1998, Vol. 78,
No. 7, pp. 366-368.
[76] - Kovalenko V.N., Golovkov Y. Z.
Basic treatment of rheumatoid
arthritis: new approaches. Revmatology in Europe 1997, Vol. 26,
Suppl. 2, Abst. 446.
[77] - Kovalenko V.N., Siniatchenko O.V., Ignatchenko G.A., Terzov
A.I., Grin V.K., Lauschkina E.M.
Systemic enzyme therapy in the gout
treatment. Ukrainskii kardiologitschnyi zurnal 1998: 1, 53-56.
[78] - Zuschlag J.-M.
Prophylactic administration of Wobenzym to
reduce consequences of sports injuries in karate fighters. MUCOS Pharma GmbH & Co, Dept. Clinical Research, Geretsried, Germany.
[79] - Kerkhoffs GM, Struijs PA, de Wit C, Rahlfs VW, Zwipp H, van
Dijk CN.
A double blind, randomised, parallel group study on the
efficacy and safety of treating acute lateral ankle sprain with oral
hydrolytic enzymes. Br J Sports Med. 2004 Aug;38(4):431-5.
[80] - Nouza K.
Physical activity and immune system. Systemic enzyme
therapy in prevention and treatment. Medicina Sportiva Boh. Slov.
1997, Vol. 6., No. 2, pp. 41 – 45.
[81] - Naumenko L. Yu.
Use of systemic enzyme therapy in the
treatment of hand injuries and their consequences. Presented at the
conference ”Current treatment aspects of wrist injuries and their
consequences”,